Replies to post #67 on Immatics NV (IMTX)

[FACT-MASTER]

That better explains the recent 100 million + capital raise.

Revenue from GSK all dried up.

[FACT-MASTER]

Thanks it's here in black and white:

https://ca.finance.yahoo.com/news/immatics-announces-third-quarter-2022-120000183.html

Cohort B – The first patient in the Phase 1b expansion cohort B was treated with IMA203 in combination with the PD-1 immune checkpoint inhibitor nivolumab in May 2022. Patients will be treated at RP2D.

Nivolumab / Opdivo = Bristol Myers Squibb

https://www.opdivo.com/

[jondoeuk]

It is Opdivo. From memory, the first patient was dosed back in May.